Nutrastar first quarter revenue increases 21.6% to $5.80 million

NewsGuard 100/100 Score

Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced record financial results for the quarter ended March 31, 2011.

Ms. Lianyun Han, CEO of Nutrastar, commented, "Nutrastar's first quarter 2011 was marked by continued sales growth, further expansion of our functional health drink distribution network and production capacity, as well as the introduction of a new entry level variation of our beverage product. Revenue growth continued at a strong and steady pace, as seen in our recorded quarterly sales growth of 21.6%. For the first quarter 2011, gross profit percentage was 76.4%, a slight decrease from 77.8% year-over-year as a result of a change in our product mix and the introduction of our beverage line, which has lower gross margins than our core commercially cultivated Cordyceps product.

"On the distribution side, we've brought our Cordyceps beverage product line into select restaurants and hotels in Changzhou City, Jiangsu Province, which has already seen good reception. More recently, we've branched into Anqing City, Anhui Province, an opportunistic marketplace for our consumer beverage product line and the next step of our commercialized rollout. In an effort to increase our footprint in these cities, we've taken initiatives to expand the reach and attractiveness of our Cordyceps drink through media advertisements, including television commercials, newspaper advertising and promotional events. In March, we announced the debut of our entry level drink "Yang Yang Ba," which is now available in Yancheng and Anqing. Looking forward, we anticipate Yang Yang Ba, an entry level priced version of our premium Cordyceps drink, will help to further grow our consumer base and drink sales within the Chinese market. We are excited for the remainder of 2011, and expect to attain our revenue guidance as stated for the year, further the growth of our product portfolio, continue our Cordyceps production capacity expansion and broaden our geographical reach in China," concluded Ms. Han.

Financial Results for Quarter Ended March 31, 2011

Revenue generated from sales of Nutrastar's consumer products for the three months ended March 31, 2011 was $5.80 million, an increase of $1.03 million or 21.6% from approximately $4.77 million for the same period in 2010. This increase was mainly attributable to the increase in demand for our core products, commercially cultivated Cordyceps Militaris and sales of our functional health beverage products.

The Company's revenue is categorized into three segments based on our consumer product portfolio. In the first quarter of 2011, revenue from our commercially cultivated Cordyceps Militaris was $5.08 million, revenue from our organic and specialty food products was approximately $0.48 million and revenue from our newly introduced functional health beverage product line was approximately $0.23 million. The functional health beverage product line was introduced in mid-November 2010 and has been rolled out in select cities in the province of Jiangsu and Anhui.

Overall gross profit was $4.43 million, an increase of $0.71 million or 19.3% from approximately $3.71 million during the same period in 2010. Gross margin was 76.4% for the three months ended March 31, 2011, a decrease of 1.4% from 77.8% in 2010. Such slight percentage decrease was mainly due to sales of our functional health beverages in the product mix which have a lower gross margin as compared to our commercially cultivated Cordyceps Militaris consumer products.

Cost of goods sold, comprising costs related to raw materials, labor and overhead, was $1.37 million for the three months ended March 31, 2011, an increase of $0.31 million, or 29.7% from approximately $1.06 million in the three months ended March 31, 2010. This increase was mainly due to the increase in sales for the core products and increase in production costs associated with the functional health beverages products. As a percentage of revenues, the cost of goods sold increased to 23.6% in the first quarter of 2011 from 22.2% in the same period of 2010. Such increase in total cost of goods sold as a percentage of sales was mainly attributable to the increase in production costs associated with the functional health beverages, which outpaced the increase in our revenues for the three months ended March 31, 2011.

Income before income tax increased approximately $0.81 million, or 25.6%, to approximately $3.95 million during the three months ended March 31, 2011 from approximately $3.14 million during the same period in 2010. As a percentage of revenues, income before income tax increased to 68.2% during the three months ended March 31, 2011 from 65.9% during the same period in 2010.  

Net income increased by approximately $0.29 million, or 10.5% to approximately $3.01 million for the three months ended March 31, 2011 from approximately $2.72 million for the same period of 2010.

Basic and diluted EPS for the three months ended March 31, 2011 was $0.20 and $0.18, based on 14.51 million and 16.27 million shares outstanding, respectively, an increase of $0.01 in basic EPS and a decrease of $0.01 in diluted EPS from the same period in 2010 when there were approximately 14.31 million basic and 14.40 million diluted shares outstanding.

Financial Position as of March 31, 2011

At March 31, 2011, the Company had cash and cash equivalents totaling $45.02 million, total assets of approximately $58.75 million, working capital of $43.03 million and stockholders' equity of $55.52 million. The Company generated $3.82 million in net cash from operating activities for the three months ended March 31, 2011.

Outlook

For the year ending December 31, 2011, based on management's current expectations, they maintain their belief that revenue will be in the range of $32.0 million to $36.0 million.

SOURCE Nutrastar International Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ginseng's hidden gems: Rare ginsenosides emerge as potent players in the future of medicine